(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares are surging more than 256 percent on Friday morning trade after the company announced that the data from the first-in-human clinical study of CRB-701 demonstrated encouraging safety and efficacy in patients with Nectin-4 positive tumors in the first human study.
The company is planning to present the results as a poster at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Currently, shares are at $30.07, up 256.22 percent from the previous close of $8.44 on a volume of 15,668,423.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
